{"id":"aphd-002","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital mycotic infections"},{"rate":"null","effect":"Increased risk of hypotension"},{"rate":"null","effect":"Increased risk of acute kidney injury"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, APHD-002 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. APHD-002's SGLT2 inhibition also has a secondary effect of reducing sodium reabsorption, which may contribute to its cardiovascular benefits.","oneSentence":"APHD-002 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:47.379Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"},{"name":"Cardiovascular risk reduction in patients with type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07008456","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of Two Different Doses of Twice Daily Distal Jejunal-release Dextrose Beads Formulations Combined With a Gel Composition Compared to Placebos in Obese Subjects With Weight Related Comorbidities","status":"RECRUITING","sponsor":"Aphaia Pharma US LLC","startDate":"2025-09-12","conditions":"Obese With Comorbidities, Obese Patients (BMI ≥ 30 kg/m²)","enrollment":102}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"APHD-002","genericName":"APHD-002","companyName":"Aphaia Pharma US LLC","companyId":"aphaia-pharma-us-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"APHD-002 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes, Cardiovascular risk reduction in patients with type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}